Firebrick Pharma Greenlights Nasodine Production in Philippines

Firebrick Pharma Limited (AU:FRE) has released an update.

Firebrick Pharma Ltd has revised its distribution strategy in the Philippines, allowing its partner, S.V. More Pharma Corporation, to manufacture the Nasodine Nasal Spray locally. This move, which eliminates the need for importation from Australia, is expected to streamline the launch of Nasodine in the Philippines as a disinfectant spray for nasal passages without requiring further clinical studies. The product is set for a Philippines launch following a year-long process of local production and regulatory approval.

For further insights into AU:FRE stock, check out TipRanks’ Stock Analysis page.